Supporting the Innovators who Optimize Therapeutic Decision-Making

Crosstree’s experience in the diagnostics and tools space is extensive, spanning routine chemistries to the most esoteric of testing, via either a product or service commercial approach. Molecular biology is reshaping the competitive landscape and Crosstree is at the forefront, facilitating synergistic transactions for a range of innovators in genomic and genetic testing and development.

No other partner is so uniquely equipped to assess and align the capabilities of diagnostics and tools companies with current market demands.

For monthly coverage of M&A, recapitalization, and growth financing transactions and to stay apprised of valuations and trends, subscribe to Crosstree’s monthly BlueBooks.


Click image to view larger

Recent Deals

WIRB-Copernicus Group (“WCG”) recapitalizes, led by Leonard Green & Partners, L.P.
Haematologic Technologies, Inc. was acquired by Edgewater Capital Partners
Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses
HistoGeneX combines with Caprion Biosciences via strategic investment from Arsenal Capital Partners